xtlbio.comCrawled Nov 22, 2026
hCDR1 is a novel compound targeting Systemic Lupus Erythematosus (SLE) through a new mechanism of action. Current SLE treatments primarily rely on immune-suppressing agents like corticosteroids and cyclosporine.
The XTLbio pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies and which address unmet medical needs. Today 3 compounds are actively being developed, all in clinical stages. XTLbio Pipeline
XTL Biopharmaceuticals develops recombinant Human Erythropoietin (rHuEPO) for treating anemia in advanced Multiple Myeloma (MM). The FDA granted its rHuEPO for MM an orphan drug designation in 2011.
Shlomo Shalev serves as a director in our company since December 2014, and starting September 2015 serves as the company's Chairman. most recently served as Chairman of the Board of Micronet, a TASE listed company. In addition to serving as a board member on a number of NASDAQ and TASE listed companies, such as OphirOptronics, Arel
Shlomo Shalev joined our Board of Directors in December 2014 and was appointed Chief Executive Officer in May, 2020. Most recently served as Chairman of the Board of Micronet, a TASE listed company. In addition to serving as a board member on a number of NASDAQ and TASE listed companies, such as OphirOptronics, Arel Communications and
Dr. Murray Urowitz earned his M.D. from the University of Toronto and completed post-graduate training in rheumatology at Johns Hopkins University and the University of Toronto. He is Professor of Medicine at the University of Toronto and Director of the Centre for Prognosis Studies in the Rheumatic Diseases.
XTL Biopharmaceuticals develops proprietary products and late-stage pharmaceutical candidates to address unmet clinical needs. Its two product candidates in development include hCDR1, a novel peptide for treating Systemic Lupus Erythematosus (SLE).
XTL Biopharmaceuticals Ltd. focuses on the acquisition and development of pharmaceutical products for the treatment of unmet clinical needs. XTL is a public company traded on the NASDAQ Capital Market (NASDAQ: XTLB) and the Tel-Aviv Stock Exchange (TASE: XTLB.TA)